# US 2025/0164504 A1 · Systems and methods to identify and treat subjects at risk for obstetrical complications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164504 A1
- Document ID: US20250164504A1
- Status: Published application
- Kind: A1
- Application number: 19/031,216
- Filed: 2025-01-17
- Published: 2025-05-22
- Earliest claimed: 2014-03-27
- Assignees: Wayne State University; The United States of America as represented by the Secretary, Department of Health and Human Service
- Applicants: Wayne State University; The United States of America as Represented by the Secretary, Department of Health and Human Service
- Inventors: Tinnakorn Chaiworapongsa; Roberto Romero; Sonia S. Hassan
- Web page: https://patentgrep.com/patent/US20250164504A1

## CPC

- G01N 33/689: {related to pregnancy or the gonads}
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 31/727: Heparin; Heparan
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 2600/158: Expression markers
- G01N 2333/475: Assays involving growth factors
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.

## Claims

### Claim 1

A method of treating an imbalance of angiogenic factor(s) and anti-angiogenic factor(s) in a pregnant female human subject, comprising administering to the subject an effective amount of a water-soluble statin, thereby treating the imbalance of angiogenic factors and anti-angiogenic factors.

### Claim 2 (depends on 1)

The method of claim 1, wherein treating of the imbalance of angiogenic factors and anti-angiogenic factors prevents an obstetrical complication.

### Claim 3 (depends on 1)

The method of claim 1, wherein the angiogenic factors comprise placental growth factor (PIGF), and/or the anti-angiogenic factors comprise soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and/or soluble endoglin (sEng).

### Claim 4 (depends on 2)

The method of claim 2, wherein the obstetrical complication comprises one or more of preeclampsia (PE), a small for gestational age (SGA) neonate, fetal death (FD), preterm labor, early-onset fetal growth restriction, anhydramnios, placental perivillous fibrin deposition, maternal floor infarction, maternal vascular underperfusion, placental lesions, placental abruption, mirror syndrome, molar pregnancy, or twin-to-twin transfusion syndrome.

### Claim 5 (depends on 4)

The method of claim 4 wherein the obstetrical complication is FD.

### Claim 6 (depends on 5)

The method of claim 5 wherein the FD is associated with maternal floor infarction or placental lesions consistent with maternal vascular underperfusion.

### Claim 7 (depends on 1)

The method of claim 1, wherein the water-soluble statin is pravastatin.

### Claim 8 (depends on 7)

The method of claim 7, wherein the effective amount of pravastatin is 20 mg/day.

### Claim 9 (depends on 7)

The method of claim 7, further comprising administering heparin and aspirin to the subject.

### Claim 10 (depends on 1)

The method of claim 1, further comprising:
identifying the subject as having or at risk of the imbalance of angiogenic factors and anti-angiogenic factors.

### Claim 11 (depends on 10)

The method of claim 10, wherein identifying the subject as having or at risk of the imbalance of angiogenic factors and anti-angiogenic factors comprises:
obtaining a blood or serum sample derived from a subject;
assaying the sample for the concentration of one or more markers selected from placental growth factor (PIGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), and soluble endoglin (sEng);
analyzing the concentrations by assessing a ratio of PIGF/sVEGFR-1 and/or PIGF/sEng in the sample;
determining a MoM maternal plasma concentration ratio of PIGF/sVEGFR-1 and/or a MoM maternal plasma concentration ratio of PIGF/sEng;
comparing the determined MoM maternal plasma concentration ratio to a threshold;
identifying a presence or risk of an imbalance of angiogenic factors and anti-angiogenic factors based on the comparison of the MoM maternal plasma concentration ratio to the threshold, wherein a MoM concentration of <0.12 for PIGF/sVEGFR-1 is indicative of an angiogenic and anti-angiogenic imbalance and a MoM concentration of <0.3 for PIGF/sEng is indicative of an angiogenic and anti-angiogenic imbalance.

### Claim 12 (depends on 11)

The method of claim 11, comprising determining a ratio of PIGF/sVEGFR-1 and a ratio of PIGF/sEng.

### Claim 13 (depends on 11)

The method of claim 11, wherein the sample is obtained:
during the third trimester of pregnancy; or
between a 30th week and a 34th week of pregnancy.

### Claim 14 (depends on 13)

The method of claim 13 wherein:
the MoM maternal plasma concentration ratio of PIGF/sVEGFR-1 of <0.12 is indicative of a risk for severe late PE and/or FD; or
the MoM maternal plasma concentration ratio of PIGF/sEng of <0.3 is indicative of a risk for severe late PE or late PE; or
the MoM maternal plasma concentration ratio of PIGF/sVEGFR-1 of <0.12 is indicative of a risk for delivery of an SGA neonate; or
the MoM maternal plasma concentration ratio of PIGF/sEng of <0.3 is indicative of a risk for delivery of an SGA neonate.

### Claim 15 (depends on 11)

The method of claim 11 wherein the sample is obtained between a 24th week of pregnancy and a 28th week of pregnancy.

### Claim 16 (depends on 15)

The method of claim 15 wherein an anti-angiogenic PIGF/sVEGFR-1 ratio is indicative of a risk for stillbirth, PE, delivery of an SGA neonate, or pre-term labor.

### Claim 17

A kit comprising protein and/or nucleotide sequences that bind to PIGF, sVEGFR-1, and sEng in a sample derived from a subject and directs diagnosis of the presence or risk of an angiogenic and anti-angiogenic imbalance based on a concentration of the bound protein and/or nucleotide sequences.

### Claim 18 (depends on 17)

The kit of claim 17, further comprising a detectable marker.

### Claim 19 (depends on 18)

The kit of claim 18, wherein the detectable marker is a radioactive isotope, enzyme, dye, fluorescent dye, magnetic bead, or biotin.

### Claim 20 (depends on 17)

The kit of claim 17 further comprising reagents to perform an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay (RIA), a Western blot, an immunoprecipitation, an immunohistochemical staining, flow cytometry, fluorescence-activated cell sorting (FACS), an enzyme substrate color method, and/or an antigen-antibody agglutination.
